UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00.

It operates through the following segments: Diagnostics and Pharmaceuticals ... Read More on RHHVF: Roche NewsMORE Related Stocks Indices Commodities ...

The Diagnostics division’s sales rose 4% year ... However, pipeline setbacks weigh on the stock. Roche also expects loss of exclusivity for key drugs to impact adversely sales to the tune ...

With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics, helping to expand patient access to personalised treatment. Basel, 31 January ...

Roche projects mid-single digit group sales growth in 2025, with core EPS growth in the high-single digit range. The company expects a CHF1.2 billion impact from the loss of exclusivity but aims to ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...